ArticleCureus2026
Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTirzepatide, a novel dual GIP/GLP-1 receptor agonist, has demonstrated superior glycemic efficacy in randomized clinical trials. However, real-world data in Indian populations remain limited.
objectiveThe primary objective of this multicenter retrospective study was to evaluate the change in glycated hemoglobin (HbA1c) at 12 weeks (three months) following initiation of tirzepatide in Indian adults with type 2 diabetes mellitus treated in routine clinical practice. Secondary objectives included assessment of changes in body weight, blood pressure, lipid parameters, hepatic fibrosis index (FIB-4), and evaluation of tolerability and treatment persistence during follow-up.
methodsThis retrospective multicenter study included 71 adults with type 2 diabetes who completed three months of tirzepatide therapy across seven centers in Lucknow, Uttar Pradesh. The primary outcome was the change in HbA1c. Secondary outcomes included body weight, blood pressure, lipid parameters, liver enzymes, FIB-4 index, and evaluation of tolerability and treatment persistence.
resultsMean HbA1c decreased significantly from 8.7 ± 1.4% to 6.9 ± 1.0% (mean change -1.8 ± 1.2%, p<0.001), with 59.2% achieving HbA1c <7% at three months. Mean body weight declined by 4.7 ± 3.2 kg (5.7%, p<0.001). Significant improvements were observed in systolic blood pressure (-5.6 mmHg), total cholesterol (-16.6 mg/dL), LDL-cholesterol (-12.2 mg/dL), HDL-cholesterol (+2.6 mg/dL), triglycerides (-46.4 mg/dL), and liver enzymes (all p<0.001). FIB-4 index decreased from 1.24 ± 0.68 to 1.08 ± 0.54 (p=0.004). Gastrointestinal adverse events occurred in 59.2% of patients, predominantly mild to moderate. The treatment discontinuation rate was 22.2%, mainly due to gastrointestinal intolerance (36%) and financial constraints (32%).
conclusionIn routine clinical practice, tirzepatide was associated with substantial glycemic improvement and meaningful weight loss at 12 weeks, along with favorable changes in cardiometabolic risk factors (blood pressure, lipids, hepatic indices). While the safety profile was consistent with global clinical trial data, real-world treatment persistence was significantly influenced by tolerability and affordability, highlighting important context-specific barriers in the Indian healthcare setting. Cost remains a key barrier to long-term use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.